Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in ...

The company's stock value has tanked before - it was once worth $1 billion.

David Reese believes that AI’s greatest impact will come from improving the thousands of human-led decisions. If Reese, the ...

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market.

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

Boris Nikolic’s career looked to be in tatters after his friendship with Jeffrey Epstein came to light in 2019. But he has ...

Kraig Biocraft Laboratories (OTCQB:KBLB) deployed one million genetically engineered silkworm eggs across multiple ...